RxDoctor Payments Data

Beverly Nelson

Nurse Practitioner · Jacksonville, FLNPI 1730619891

Payments from drug & device makers

$8,129in general payments, 2019–2025

Across 424 payments — averaging $19.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Bayer$749
  • AbbVie$606
  • GSK$530
  • Amgen$495
  • Lilly USA, LLC$491
  • plus $4K from 33 others

What the payments were for

  • Food & beverage$8,129100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,129 in reported general payments places this provider in the 95th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$73,720
Medicare patients
56
Services billed
1,326

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide43$59,528
JardianceEmpagliflozin26$32,874
FarxigaDapagliflozin Propanediol13$16,891
LinzessLinaclotide13$11,783
VascepaIcosapent Ethyl11$6,859
XareltoRivaroxaban13$6,583
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$2,146
Albuterol Sulfate HfaAlbuterol Sulfate40$1,677
Omeprazole34$479
Gabapentin29$472
Losartan Potassium50$427
Trazodone Hcl32$406
Atorvastatin Calcium49$405
Metoprolol Succinate34$319
Levothyroxine Sodium37$281

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$491$59,52843 claims
Boehringer IngelheimJardiance$150$32,87426 claims
AstraZenecaFarxiga$1,546$16,89113 claims
AbbVieLinzess$606$11,78313 claims
Johnson & JohnsonXarelto$31$6,58313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →